Clinical trial NCT05418907: Exendin PET/CT for Imaging of Paragangliomas
Official title: Exendin PET/CT for Paragangliomas
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Paraganglioma
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
First posted: 2022-06-14
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with biochemically proven PGL

Brief summary: Functional imaging of paragangliomas (PGLs) is not unequivocal. Existing functional imaging modalities show good but variable results in PGLs, warranting the search for additional molecular imaging targets. Investigators aim to evaluate the glucagon-like peptide 1 receptor (GLP-1R) as a novel target for molecular imaging of PGLs. For this purpose investigators will use the tracer 68Ga-NODAGA-exendin 4 for positron emission tomography/computed tomography (PET/CT) imaging.

Detailed description: Rationale:

Functional imaging of paragangliomas (PGLs) is not unequivocal. Existing functional imaging modalities show good but variable results in PGLs, warranting the search for additional molecular imaging targets. Investigators aim to evaluate the glucagon-like peptide 1 receptor (GLP-1R) as a novel target for molecular imaging of PGLs. For this purpose investigators will use the tracer 68Ga-NODAGA-exendin 4 for positron emission tomography/computed tomography (PET/CT) imaging.

Objective:

The primary objective is to examine the feasibility of 68Ga-exendin-4 PET/CT for localization and functional characterization of PGLs.

Study design:

In this prospective pilot imaging study 68Ga-exendin-4 PET/CT will be performed in 10 patients with confirmed PGL who have undergone CT, somatostatin receptor (SSTR) PET/CT and 18F-FDG PET/CT (as standard diagnostic procedures) and are scheduled for surgery. 100 ± 10 MBq 68Ga-NODAGA-exendin-4 will be administered to 10 patients in total. In the first 5 patients PET/CT imaging will be performed 1, 2 and 4 hours after injection to determine the optimal imaging timepoint for the remainder of the patients, which will be applied in the remaining patients.

The images will be reconstructed and evaluated by a nuclear medicine physician who is blinded to the results of the CT, SSTR PET/CT and 18F-FDG PET/CT to assess tumor detection. Additionally, quantitative analysis of 68Ga-exendin-4, SSTR PET and 18F-FDG PET/CT images will be performed. After the patients have undergone surgery, immunohistochemical analysis of surgical specimens will be performed to assess GLP-1R expression, which will be compared with in vivo tracer uptake.

Eligibility criteria: Inclusion Criteria:

* Proven sympathetic PGL with a single tumor detected using standard diagnostic imaging
* No evidence of metastatic disease
* CT, SSTR PET/CT and 18F-FDG PET/CT performed (golden standard diagnostic imaging)
* Scheduled for surgery
* Able to sign informed consent

Exclusion Criteria:

* Breast feeding
* Pregnancy or the wish to become pregnant within 1 month
* Calculated creatinine clearance below 40ml/min
* Evidence of other malignancy than PGL in conventional imaging (suspicious liver, bone and lung lesions)
* Age \< 18 years
* Not able to sign informed consent

Primary outcomes:
measure: detection rate of PGL's using 68Ga-exendin-4 PET/CT
timeFrame: 1 year
Secondary outcomes:
measure: optimal timepoint for imaging PGLs using 68Ga-exendin-4 PET/CT
timeFrame: After inclusion of the first 5 patients (up to 6 months)
Other outcomes:
Locations:
city: Nijmegen
country: Netherlands
facility: Radboud University Medical Center
Study officials:
References: